CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home »

ONCOLOGY. Vol. 10 No. 10
The Paulino Article Reviewed 

Current Issues in the Diagnosis and Management of Wilms' Tumor

By Daniel M. Green, MD, Roswell Park Cancer Institute, Buffalo, New York | October 1, 1996

Paulino has thoughtfully reviewed the etiology, diagnosis, and management of Wilms' tumor. Investigators from the National Wilms' Tumor Study Group (NWTSG) first divided Wilms' tumors into two groups: those with a favorable histology and those with an unfavorable histology.[1]

The unfavorable histology group included those Wilms' tumors with focal or diffuse anaplasia[2] and two histologic patterns now recognized to be entities distinct from Wilms' tumor--clear cell sarcoma of the kidney and rhabdoid tumor of the kidney.[3] These two non-Wilms' tumors are associated with central nervous system metastases and second primary tumors that originate within the central nervous system.[4,5] Thus, imaging of the central nervous system must be included in the pretreatment staging of these two subgroups of patients.

In addition to the studies cited by Paulino, investigators from the Emma Kinderzuikenhuis in Amsterdam, using criteria identical to those employed in the report from St. Jude Children's Research Hospital, reported that only 8.8% (7/79) of children who received preoperative combination chemotherapy achieved tumor shrinkage sufficient to make them candidates for partial rather than total nephrectomy.[6] Thus, there is no compelling evidence that neoadjuvant chemotherapy will result in less radical surgery in a significant number of patients.

The Dana-Farber Pilot Study

The pilot study conducted at the Dana-Farber Cancer Institute was based on the results of treatment at The Childrens Hospital, Boston from 1929 through 1977. It was there that a favorable outcome for infants treated with surgery alone was first noted.[7] Subsequent analyses of data from the NWTSG demonstrated that intensive chemotherapy regimens did not improve the prognosis for infants younger than 24 months with stage I, favorable histology Wilms' tumors that weighed less than 550 grams.[8] These children with stage I, favorable histology Wilms' tumors also tended to have favorable prognostic variables, as defined by Weeks et al.[9]

The radiation therapy doses required for children with clear cell sarcoma of the kidney and Wilms' tumor with anaplasia have been modified, based on the data referenced by Paulino. Thus, in NWTS 5, the age-adjusted doses are not employed for the treatment of these two groups of children. All children receive a nominal abdominal radiation therapy dose of 1,050 cGy.

Paulino reviews the chemotherapeutic management of Wilms' tumor as recommended by NWTS 1, 2, and 3. In regard to standard (daily, divided dose) vs "pulse-intensive" (intermittent single dose) schedules for dactinomycin(Drug information on dactinomycin) and doxorubicin(Drug information on doxorubicin), NWTS 4 [10] showed no statistically significant difference in relapse-free or overall survival between the two regimens. Hematologic toxicity was less severe and the dose intensity was greater for those treated using the pulse-intensive schedule.[11] Thus, the pulse-intensive regimen is now recommended as standard treatment.

Long-Term Complications

In addition to the skeletal sequelae discussed by Paulino, two other important long-term complications of treatment are second primary tumors [10] and cardiac toxicity related to treatment with doxorubicin[11]. The cumulative percentage of children treated with doxorubicin for Wilms' tumor on NWTS 2 and 3 who developed congestive heart failure was 1.7% at 15 years after diagnosis. The onset was 1.3 to 11.7 years after diagnosis of Wilms' tumor, with half of the eight cases occurring 8.8 to 11.7 years after diagnosis. The percentage increased to 5.4% of those whose treatment included whole-lung irradiation, compared to 1.0% of those whose treatment did not.[11] Both prior treatment with radiation and prior treatment with doxorubicin increased the relative risk of developing a second malignant tumor.[10]

 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.



Arnold C. Paulino, MD


1. Beckwith JB, Palmer NF: Histopathology and prognosis of Wilms' tumor. Cancer 41:1937-1948, 1978.

2. Faria P, Beckwith JB, Kishra K, et al: Focal versus diffuse anaplasia in Wilms' tumor: New definitions with prognostic significance. A report from the National Wilms' Tumor Study Group. Am J Surg Pathol 20:909-920, 1996.

3. Murphy WM, Beckwith JB, Farrow GM: Tumours of the kidney, bladder, and related urinary structures. Atlas of Tumor Pathology, 3rd Series, Fascicle 11. Washington DC, Armed Forces Institute of Pathology, 1994.

4. Bonnin JM, Rubinstein LJ, Palmer NF, et al: The association of embryonal tumors originating in the kidney and in the brain. Cancer 54:2137-2146, 1984.

5. Weeks DA, Beckwith JB, Mierau GW, et al: Rhabdoid tumor of kidney. Am J Surg Pathol 13:439-458, 1989.

6. Moorman-Voestermans CGM, Staalman CR, Delamarre JFM: Partial nephrectomy in unilateral Wilms' tumor is feasible without local recurrence (abstract). Med Pediatr Oncol 23:218, 1994.

7. Green DM, Jaffe N: The role of chemotherapy in the treatment of Wilms' tumor. Cancer 44:52-57, 1979.

8. Green DM, Breslow NE, Beckwith JB, et al: The treatment of patients less than 2 years of age with small, stage I/favorable histology Wilms' tumor. A report from the National Wilms' Tumor Study. J Clin Oncol 11:91-95, 1993.

9. Green DM, Beckwith JB, Weeks DA, et al: The relationship between microsubstaging variables, tumor weight and age at diagnosis of children with Stage I/favorable histology Wilms' tumor. A report from the National Wilms' Tumor Study. Cancer 74:1817-1820, 1994.

10. Green DM, Breslow NE, Evans I, et al: The effect of chemotherapy dose intensity on the hematological toxicity of the treatment for Wilms' tumor. A report from the National Wilms' Tumor Study. Am J Pediatr Hematol Oncol 16:207-212, 1994.

11. Green D, Breslow N, Beckwith J, et al: A comparison between single dose and divided dose administration of dactinomycin and doxorubicin. A report from the National Wilms' Tumor Study Group. Proc Am Soc Clin Oncol 15:457, 1996.


 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
IMAGE IQ

Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
James B. Yu, MD1 , May 17, 2013

A 70-year-old man with a history of localized prostate cancer treated with whole-pelvis radiation therapy with a boost to the prostate, in conjunction with androgen deprivation therapy 7 years prior, presented with lower back pain. A bone scan revealed an area of activity in the sacrum. What is the most likely diagnosis?

More Image IQs 

 
FROM PHYSICIANS PRACTICE
Primary Care Can't Thrive Without Nurse Practitioners
Courtney H. Lyder, ND,  May 17, 2013
With a projected shortfall of primary-care physicians, it's time for alternate solutions to patient care. Nurse practitioners are one logical remedy.
VWhat Physicians Can Learn from the Allscripts EHR Lawsuit
Marisa Torrieri,  May 16, 2013
Lawsuit prompts question: What should physicians do to ensure they end up with a great EHR instead of buyer’s remorse?
Eight Ways ICD-9 Will Still Matter to Medical Practices
Brenda Edwards, CPC,  May 15, 2013
What should your medical practice do with your ICD-9-CM book after October 1, 2014? Keep it.
Seven Ways Technology Can Speed Up Patient Collections
Cheyenne Brinson,  May 15, 2013
Failing to adopt widely available billing and collections technology can cost medical practices big. Here's how to do it right.
Four Reasons Private Medical Practice is Becoming Extinct
Carol Stryker,  May 15, 2013
It’s becoming increasingly difficult for private medical practices to thrive. Here’s what’s driving the trend toward consolidation.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Colorectal Lesions
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Skin Lesions
  • Slide Show: Squamous Cell Carcinoma of the Head and Neck
  • “This Is My Last Day on Earth”
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Colorectal Lesions
  • ONS: Understanding Spirituality and How It Can Be Used to Help Patients
  • New AUA Guidelines for Prostate Cancer Screening
  • 50 Shades of Pink—And Why It Helps to Know the Difference
  • Genomics Studies Identify Testicular Cancer Risk Variants
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • FDA Approves Erlotinib (Tarceva) as First-Line Lung Cancer Therapy for Certain Patients
Click here to subscribe to our newsletter
 
COMMENTS
  • Most Commented
  • Most Recent
  • “This Is My Last Day on Earth”
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
  • Patient Quality of Life Endpoints in Oncology Trials, Part II
  • Who's Coding Whom?
  • “How Do I Say This Nicely? Your Oncologist Wasn't Following Guidelines”
  • Cancer Metabolism as a Therapeutic Target
  • Study: Cholesterol Drugs Reduced Risk of Prostate Cancer Death
  • “This Is My Last Day on Earth”
  • ONS: Safe Handling of Chemotherapy
  • Financial Toxicity, Part II: How Can We Help With the Burden of Treatment-Related Costs?
Click here to subscribe to our newsletter



CancerNetwork on Facebook

CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy